Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States
October 31 2023 - 7:57AM
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical
robotics for minimally invasive endovascular intervention, today
announced the first patients in the United States have been treated
successfully utilizing Abbott’s EnSite™ X EP System integrated with
Stereotaxis’ Robotic Magnetic Navigation System.
The integration of Abbott’s leading cardiac
mapping system and Stereotaxis’ advanced robotic technology, first
announced at Heart Rhythm 2023, combines highly detailed real-time
diagnostic information with the unprecedented precision and
stability of robotics during therapy delivery. The first integrated
procedures in the US were completed by physicians at Weill Cornell
Medical Center, Mount Sinai Morningside, Banner University Medical
Center Phoenix, and Overland Park Regional Medical Center.
“We are very pleased with how well these initial
procedures went and the progress toward open interoperability with
robotics in electrophysiology,” said Dr. Dhanunjaya Lakkireddy,
Electrophysiologist and Executive Medical Director of Kansas City
Heart Rhythm Institute at Overland Park Regional Medical Center.
“Combining Abbott’s leading cardiac mapping system with
Stereotaxis’ advanced robotic technology enhances precision and
streamlines procedure workflow, ultimately benefiting the patients
we are dedicated to treating.”
“Abbott and Stereotaxis have each played leading
roles in advancing care for the most complex and difficult to treat
arrhythmia patients,” added Dr. Jim Cheung, Associate Director of
Cardiac Electrophysiology at Weill Cornell Medical Center. “We are
delighted to be able to use both technologies in an integrated
fashion, leveraging the combined benefits in diagnosis and therapy
for our patients.”
“As long-term users of both Abbott and
Stereotaxis technology, we appreciate the ability to use these
technologies together with a smooth integrated workflow,” said Dr.
Ranjit Suri, Professor of Medicine at the Icahn School of Medicine
at Mount Sinai. “Increased physician choice and technology
interoperability benefits patients, physicians and providers.”
“The success of these procedures demonstrates
the unmatched potential and importance of increased collaboration
in the field of electrophysiology,” added Dr. J. Peter Weiss,
Director of Ventricular Arrhythmia Management and Robotics at
Banner University Medicine Heart Institute. “The combined benefits
of advanced mapping and robotic technologies allows us to envision
a new era of cardiac care where personalized therapy is designed
and delivered to each individual patient. It's a game-changer for
the field."
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100Investors@Stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2024 to May 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From May 2023 to May 2024